Form 4 for RNAZ Transcode Therapeutics, Inc.
Accepted 2023-10-02 00:00:00 ET · period of report 2023-09-28 · accession 0001104659-23-105925 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-02 | 2023-09-28 | RNAZ | Fitzgerald Thomas A | CFO, Dir | P - Purchase | $0.51 | +49.4K | 56.3K | +708% | +$25.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-28 | P | A | 49,350 | $0.51 | 56,318 | D | — | — | (F2) Reported amount reflects a 1-for-20 reverse stock split of the Issuer's common stock, which became effective as of May 22, 2023. |